Tina Baker, Hoda Sharifian, Paul J Newcombe, Patrick G Gavin, Mark N Lazarus, Madhu Ramaswamy, Wendy I White, Nicola Ferrari, Daniel Muthas, Raj Tummala, Eric F Morand, Richard Furie, Edward M Vital, Chris Chamberlain, Adam Platt, Hussein Al-Mossawi, Philip Z Brohawn, Eszter Csomor
INTRODUCTION: Anifrolumab is a type I interferon (IFN) receptor 1 (IFNAR1) blocking antibody approved for treating patients with systemic lupus erythematosus (SLE). Here, we investigated the immunomodulatory mechanisms of anifrolumab using longitudinal transcriptomic and proteomic analyses of the 52-week, randomised, phase 3 TULIP-1 and TULIP-2 trials. METHODS: Patients with moderate to severe SLE were enrolled in TULIP-1 and TULIP-2 and received intravenous anifrolumab or placebo alongside standard therapy...
April 3, 2024: Annals of the Rheumatic Diseases